TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05847530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icon
Description: Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discretion. At the discretion of the PI, additional follow-up visits may take place to observe the time course of skin reactions after treatment and/or to assess if the skin condition continues to improve beyond 3 months after treatment.
Study: NCT05894642

Intervention type: BEHAVIORAL
Intervention: 0
Description: It is a case-control study, cross-sectional, so there is no intervention possible.
Study: NCT05129878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and OHI
Description: patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive scaling and oral hygiene instructions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral Hygiene instructions
Description: patients with PCOS on combined oral contraceptives (COCs) having gingivitis will receive oral hygiene instructions only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and oral hygiene instruction
Description: Systemically Healthy (age and BMI matched) females with gingivitis will receive with OHI and Scaling
Study: NCT06072937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntelliStent
Description: Staged implantation of IntelliStent. The system comprises a nitinol self-expanding stent with a hollow element delivered over-the-wire into the main pulmonary artery or its left and right branches, using an 18 Fr transfemoral introducer sheath. The stent consists of two sections, one with a larger diameter and one with a smaller diameter, available in 6 sizes suitable for vessel sizes ranging from 20mm to 30 mm. Additional smaller sizes are currently under development.
Study: NCT06197035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coping With and Caring for Infants With Special Needs
Description: The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
Study: NCT06313567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine group
Description: 500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: observation
Study: NCT04752111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esmolol
Description: administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery
Study: NCT06112314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brenetafusp
Description: Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brenetafusp
Description: Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Concentrate for solution for infusion at a unit dose of 10 mg/mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Concentrate for solution for infusion at a unit dose of 10 mg/mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Concentrate for solution for infusion at a unit dose of 10 mg/mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Relatlimab
Description: Concentrate for solution for infusion at a unit dose of 16 mg/mL.
Study: NCT06287112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic transpapillary gallbladder drainage (ETGBD)
Description: Fully covered self-Expandable metal stent with Endoscopic transpapillary gallbladder drainage (ETGBD) in patient with cystic duct low insertion
Study: NCT04741880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Will be sent to Group L a 10 ml syringe of 2% lidocaine and 200 ml of lidocaine solution at 8mg.ml-1 (80ml of 2% lidocaine associated with 120ml 0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Group S will be sent a 10 ml syringe of 1% lidocaine and 200 ml of saline solution (0.9% sodium chloride)~A syringe with 10 ml of solution and a bag with 200 ml of solution indistinguishable between the groups, with the identification of the patient by label prepared specifically for the study will be prepared by the Pharmacy personal. The bag and the solution will be sealed in a waterproof and opaque envelope and sent to the Operating Theatre (OT). The envelope will be stored in the refrigerator of the sector between 3º C and 8º C until the patient is sent to the operating room, when the drugs will be sent to the operating room. At the time designated for the start of the intervention, a bolus of 0.075 ml.kg-1 of the syringe solution, followed by 0.25 ml.kg-1.h-1 in the infusion pump of the solution in the bag will be administered.
Study: NCT06171399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Boost descriptor
Description: Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No descriptor (control)
Description: Participants in the nine intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the product descriptors of interest. All participants will see the same four products, and each condition will see the products with the same descriptor.
Study: NCT05662956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with azacitidine and CAG
Description: Induction:~VA regimen：~Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21);~Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.~CAG regimen：~Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7;~Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7;~Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×10\^9/L；~Consolidation:~Drug: Cytarabine 3g/m2 q12h on days 1-3.
Study: NCT06197035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
Study: NCT05627622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp health education message
Description: stone-prevention information on a monthly basis, using personal WhatsApp messages
Study: NCT06443736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized perineal massage
Description: Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary prevention
Description: Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
Study: NCT05977088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetetive Transcranial Magnetic Stimulation
Description: .Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetetive Transcranial Magnetic Stimulation
Description: .Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.
Study: NCT04780464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide Oral Product
Description: 100 mg BD on day 1 to day 7 of each 14 day cycle until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD for those Countries where Prednisolone in tablets is not available
Study: NCT06169111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGulatory T cells in Autism induced by maternal Immune activation
Description: REGulatory T cells in Autism induced by maternal Immune activation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: REGulatory T cells in Autism induced by maternal Immune activation
Description: REGulatory T cells in Autism induced by maternal Immune activation
Study: NCT06254053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconia reinforced glass ionomer
Description: Restorative material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer cement
Description: Restorative material
Study: NCT05712408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 800g Challenge
Description: The intervention will involve 8 weeks of an online diet program. Outcomes testing will occur at baseline and post-intervention (following 8 week diet program). During the first 4 weeks, participants will receive educaitonal material and log their daily points in an online application and attend a weekly check-in call with members of the research team. During weeks 5-8, participants will log their daily points in the online application.
Study: NCT06266455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Fortification
Description: Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Fortification
Description: Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Fortification
Description: Fortification with liquid, bovine-based HMF to assumed human milk content of 24kcal/oz

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjustable Fortification
Description: Additional liquid protein supplementation to maintain serum BUN levels within goal range (9-14mmol/dL)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjustable Fortification
Description: Additional liquid protein and/or MCT oil supplementation to maintain protein, fat, and energy intake within goal range based upon mid-infrared human milk analysis
Study: NCT05970315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPC
Description: Participants will have an encounter with a facilitator who will identify priorities (outcome goals and care preferences) from the dyads and transmits them in the electronic health records (EHR), and a follow-up encounter with their usual geriatric care provider to decide upon changes in their care that align with the identified priorities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will have a geriatric clinic visit with a geriatrician that acts as their primary care provider (PCP) , in which the dyads will be encouraged by an unblinded study coordinator to ask about reducing medication burden.
Study: NCT05981560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A - Closed Chain Exercise
Description: 17 participants were in experimental group giving them closed chain exercise plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B - Neuromuscular Training Exercise
Description: 17 participants were in experimental group giving them neuromuscular training plan of 5 exercises, 10reps x 3sets each, on alternate 3 days per week for duration of 4-weeks, all values measured before and after 4-weeks.
Study: NCT05018390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Participants will be positioned on an exam table supine, seated, or decubitus. Osteopathic manipulations will consist in corrective micro-movements applied on synovial joints, on the skull, the teeth and/or visceral structures of the abdomen or the thorax. Local pressures won't exceed a few tens of grams/cm². Practitioners will realize between 15 and 25 technical gestures per participant. Treatment will last 30 minutes (plus or minus 5 minutes) on average. The technical gestures are referenced in the Glossary of Osteopathic Terminology published by the American Association of Colleges of Osteopathic Medicine (2017).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic manipulative treatment
Description: Participants will be positioned on an exam table supine, seated, or decubitus. They will receive 20 gestures that will be standardized and different from actual osteopathic manipulations (but not identifiable as sham manipulations by the participants). The duration of the sham treatment will be the same as the actual treatment.
Study: NCT06401382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A modified aligner appliance with NiTi springs
Description: The modified aligner appliance will be used until the final position is achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed appliances
Description: The traditional fixed appliances with a standard prescription will be used.
Study: NCT05762276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXX-401
Description: A synthetic PCSK9 peptide-based immunotherapy
Study: NCT06384833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: NAC (effervescent) 600mg 1 tab PO OD for 45 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pharmacologically inactive substance
Study: NCT05602324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lauric Acid and Berberine
Description: intervention (15 ml lauric acid + 1000 mg berberine) will be provided daily to participants in this arm for the duration of time that they receive enteral nutrition for a period of 14 days maximum
Study: NCT04952350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
Study: NCT05748587

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Iron
Description: Serum iron levels in study groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Iron
Description: Serum iron levels in study groups

Intervention type: DIAGNOSTIC_TEST
Intervention: RBCs Alpha-synuclein
Description: α-syn levels in RBCs

Intervention type: DIAGNOSTIC_TEST
Intervention: RBCs Alpha-synuclein
Description: α-syn levels in RBCs

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Soluble lymphocyte activation gene
Description: sLAG-3 in the serum of study groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Soluble lymphocyte activation gene
Description: sLAG-3 in the serum of study groups

Intervention type: RADIATION
Intervention: Brain computed tomography
Description: Brain CT of patients after admission

Intervention type: RADIATION
Intervention: Brain computed tomography
Description: Brain CT of patients after admission

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Iron
Description: Iron in brain homogenate of rats

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Iron
Description: Iron in brain homogenate of rats

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Iron
Description: Iron in brain homogenate of rats

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Alpha-synuclein
Description: α-syn expression in rat's brain

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Alpha-synuclein
Description: α-syn expression in rat's brain

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Alpha-synuclein
Description: α-syn expression in rat's brain

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain lymphocyte activation gene
Description: LAG-3 expression in rat's brain

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain lymphocyte activation gene
Description: LAG-3 expression in rat's brain
Study: NCT05245474

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)
Description: Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
Study: NCT05748587

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain lymphocyte activation gene
Description: LAG-3 expression in rat's brain

Intervention type: DRUG
Intervention: Deferoxamine
Description: intramuscular deferoxamine (200 mg/kg) injection to rats
Study: NCT04603326

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids
Study: NCT05001646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-home resonance-based electromagnetic field protection device
Description: Participants will have an in-home EMF protection device